Microbiome and Autoimmune Panels for Cancer
(INSPECT-IO Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to determine if certain factors in the gut and immune system can predict side effects in patients with advanced solid tumors receiving immunotherapy. Researchers will analyze blood and stool samples to better understand these connections. Participants must have an incurable solid tumor and be receiving immunotherapy at Princess Margaret Cancer Centre. No additional hospital visits are required, as the study uses samples and data from existing treatments. As an unphased trial, this study allows patients to contribute to important research that could enhance future cancer treatments.
Why are researchers excited about this trial?
Researchers are excited about this trial because it aims to discover whether analyzing the intestinal microbiome and autoimmune panels can predict toxicity in patients undergoing immunotherapy for cancer. Unlike existing treatments that focus on managing side effects after they occur, this approach could proactively identify patients at higher risk of experiencing severe side effects. This predictive capability could personalize and improve the safety of immunotherapy, potentially leading to better patient outcomes and more targeted treatment plans.
Who Is on the Research Team?
Anna Spreafico, MD
Principal Investigator
Princess Margaret Cancer Centre
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Sample Collection
Collection of stool and blood samples at multiple time-points for microbiome and autoimmune panel analysis
Follow-up
Participants are monitored for safety and effectiveness after sample collection
What Are the Treatments Tested in This Trial?
Find a Clinic Near You
Who Is Running the Clinical Trial?
University Health Network, Toronto
Lead Sponsor